Eli Lilly joins a troika of Big Pharmas that have tied up to a low-profile biotech with big aspirations in autoimmune disease, cancer

Eli Lilly $LLY has followed 3 major league pharma players down the deal path to ImmuNext, a biotech you may not know a whole lot about.